Author

Dan Levitt

Observed names: D Levitt, D. Levitt, Levitt, D

Institution: Dynavax Technologies (United States)

Observed institutions: Roswell Park Comprehensive Cancer Center, Dynavax Technologies (United States), Geron (United States), PDL BioPharma (United States), Institut of Research in Solar Energy and New Energies

OpenAlex ID: A5072359954

Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies

2002 · G. C. Jayson, J. Zweit, et al. · JNCI Journal of the National Cancer Institute · 258

PDF

Telomerase Activity and Survival of Patients With Node-Positive Breast Cancer

1997 · G. M. Clark, C. K. Osborne, et al. · JNCI Journal of the National Cancer Institute · 139

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

2005 · Scott A. Halperin, Simon Dobson, et al. · Vaccine · 135

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy.

1990 · M Hirsh, A Lipton, et al. · Journal of Clinical Oncology · 69

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

2005 · Gordon C. Jayson, Clive Mulatero, et al. · European Journal of Cancer · 51

A HUMANIZED ANTI-CD3 ANTIBODY, HuM291, WITH LOW MITOGENIC ACTIVITY, MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES

1999 · Di-Hwei Hsu, Jia Dong Shi, et al. · Transplantation · 45

A Phase II Trial of Concomitant Human Interleukin-2 and Interferon-??-2a in Patients with Disseminated Malignant Melanoma

1993 · Robert P. Whitehead, Robert Figlin, et al. · Journal of Immunotherapy · 28

Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkinʼs Lymphoma and Hodgkinʼs Disease

1991 · Z. P. Bernstein, L. Vaickus, et al. · Journal of Immunotherapy · 26

Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I Toxicity, Pharmacokinetic and Pharmacodynamic Study.

2001 · Gordon C. Jayson, C Mulatero, et al. · Research Explorer (The University of Manchester) · 19

Phase 2/3 Study of the Novel Vaccine Amb a 1 Immunostimulatory Oligodeoxyribonucleotide Conjugate AIC in Ragweed-Allergic Adults

2006 · W. Busse, G. Gross, et al. · Journal of Allergy and Clinical Immunology · 15

Both species of chlamydia and two biovars of Chlamydia trachomatis stimulate mouse B lymphocytes.

1986 · D Levitt, R Danen, et al. · The Journal of Immunology · 14

Novel Amb a 1 CpG Oligodeoxyribonucleotide Conjugate Ragweed Vaccine Administered to Children

2006 · A.S. Nayak, I. Tripathy, et al. · Journal of Allergy and Clinical Immunology · 6

Development and regulation of chlamydia-responsive murine B lymphocytes.

1987 · D Levitt, R Danen · The Journal of Immunology · 4

Evaluation of safety and clinical efficacy of higher dose immunotherapy with AIC (immunostimulatory DNA conjugated with Amb a 1) in patients with ragweed-induced seasonal allergic rhinitis (SAR)

2005 · A.R. Vaishnav, S.B. Whaley, et al. · Journal of Allergy and Clinical Immunology · 3

PDF

Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.

1990 · E E Holdener, R P Emmons, et al. · PubMed · 3

PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study

2001 · G.C. Jayson, J. Zweit, et al. · European Journal of Cancer · 2

33. A phase I clinical trial of anti-angiogenic therapy: pharmacokinetics by PET in relation to pharmacodynamics by dynamic MR with implications for future study design

2002 · P. J. Julyan, J. Zweit, et al. · Nuclear Medicine Communications

Pharmacokinetics of a phase I clinical trial of anti-angiogenic therapy - Relationship to pharmacodynamics by dynamic-MR and implications for future study design.

2002 · PJ Julyan, Jamal Zweit, et al. · Research Explorer (The University of Manchester)

A Phase I/ii Dose Escalation Study of the Humanized Anticd3 Antibody Hum291.

2000 · Bruce Kaplan, Doug Norman, et al. · Transplantation

A HUMANIZED ANTI-CD3 ANTIBODY HuM291 MEDIATES COMPLETE AND REVERSIBLE T-CELL DEPLETION IN CHIMPANZEES

1999 · Di-Hwei Hsu, Jia Dong Shi, et al. · Transplantation

Perfluorinated C10 saturated fatty acid is toxic for both eucaryotic and procaryotic cell systems

1987 · Alan Liss, Joanne C. Pfeil, et al. · Toxicology

Demonstration of rare (unique) and frequent (shared) idiotopes in mice and humans using hybridoma anti-tepc-15 antibodies. Abstr.

1981 · Bach, M, Wittner, M, et al. · The Mouseion at the JAXlibrary (Jackson Laboratory)

Works count: 22

Citation count: 817

H-index: 11

I10-index: 11